

Applicant : Patrick Cadet et al.  
Serial No. : 10/080,917  
Filed : February 22, 2002  
Page : 2 of 3

Attorney's Docket No.: 09598-006001 / R1321-200

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 – 32 (Cancelled).

33. (New) An isolated nucleic acid primer for amplifying nucleic acid encoding a sequence of a mu3 opiate receptor having higher affinity for morphine than for DAMGO, wherein said primer comprises at least a 15 nucleotide sequence set forth in SEQ ID NO:1 with or without a single nucleotide insertion, single nucleotide deletion, or single nucleotide substitution.

34. (New) The primer of claim 33, wherein said at least a 15 nucleotide sequence is set forth in SEQ ID NO:1 without an insertion, deletion, or substitution.

35. (New) The primer of claim 33, wherein said at least a 15 nucleotide sequence is set forth in SEQ ID NO:1 with a single nucleotide insertion.

36. (New) The primer of claim 33, wherein said at least a 15 nucleotide sequence is set forth in SEQ ID NO:1 with a single nucleotide deletion.

37. (New) The primer of claim 33, wherein said at least a 15 nucleotide sequence is set forth in SEQ ID NO:1 with a single nucleotide substitution.

38. (New) The primer of claim 33, wherein said at least a 15 nucleotide sequence is between 15 and 30 nucleotides in length.